Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Comparative Pharmacology of Δ9-Tetrahydrocannabinol and its Metabolite, 11-OH-Δ9-Tetrahydrocannabinol
Louis Lemberger, … , Robert Forney, Howard Rowe
Louis Lemberger, … , Robert Forney, Howard Rowe
Published October 1, 1973
Citation Information: J Clin Invest. 1973;52(10):2411-2417. https://doi.org/10.1172/JCI107431.
View: Text | PDF
Research Article Article has an altmetric score of 69

Comparative Pharmacology of Δ9-Tetrahydrocannabinol and its Metabolite, 11-OH-Δ9-Tetrahydrocannabinol

  • Text
  • PDF
Abstract

A comparison of the psychologic and physiologic effects of intravenously administered Δ9-tetrahydrocannabinol (Δ9-THC) and 11-hydroxy-Δ9-tetrahydrocannabinol (11-OH-Δ9-THC) was carried out in nine casual marihuana smokers. A marked tachycardia and psychologic “high” occurred within 3-5 min after the i.v. administration of 11-OH-Δ9-THC (1 mg) to all subjects. In contrast, the peak psychologic “high” was delayed 10-20 min after the i.v. administration of Δ9-THC (1 mg). There was some individual variation in response among subjects. Psychologic effects correlated well with plasma levels of unchanged [3H]11-OH-Δ9-THC. About 75% of the administered radioactive dose was excreted in urine (25%) and feces (50%) after [3H]11-OH-Δ9-THC administration. The disposition, excretion, and metabolism of [3H]11-OH-Δ9-THC appear to be similar to that previously reported after [14C]Δ9-THC administration. These findings, in conjunction with the marked psychologic high seen after 11-OH-Δ9-THC, suggest that in man, Δ9-THC, the active constituent in marihuana, is converted to 11-OH-Δ9-THC, which is in part responsible for the psychologic effects.

Authors

Louis Lemberger, Robert Martz, Bruce Rodda, Robert Forney, Howard Rowe

×

Full Text PDF

Download PDF (1.05 MB)

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 7 news outlets
Posted by 3 X users
Referenced in 1 patents
Referenced in 1 Wikipedia pages
83 readers on Mendeley
See more details